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Abstract We evaluated the state of hepatocellular car-
cinoma (HCC) and the liver after ion beam therapy by
analyzing the apparent diffusion coefficient (ADC). In this
retrospective study, we evaluated 13 HCC lesions in 10
patients who underwent magnetic resonance imaging
before and after therapy. Diffusion-weighted imaging was
performed with use of b values of 0, 150, and 800 s/mm2.
The ADC was determined for the tumor, irradiated liver,
and normal liver. The maximum size of the tumor was
measured, and reduction in tumor size was determined as a
ratio of the maximum size of the diameter of the tumor. We
compared the ADC before and after the therapy with the
reduction in tumor size ratio. The reduction in tumor size
ratio was compared with the ADCs of the tumors. The
ADC of the tumor and the irradiated liver were signifi-
cantly higher after therapy than before therapy. The ADC
of the normal liver was not significantly different before
and after therapy. The reduction ratio increased signifi-
cantly (R = 0.73, P = 0.006) after therapy at the second
follow-up when compared with after therapy at the first
follow-up. No correlation was found between the reduction
ratio and the ADC of the tumor in each follow-up.
Inflammation of the liver occurs after treatment as a result
of radiation doses from the ion beam, and the tumor
reaches a state of necrosis. ADC value analysis provides a
non-invasive assessment and yields focal information
regarding the tumor and liver before and after ion beam
therapy.
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1 Introduction
Hepatocellular carcinoma (HCC) is one of the five main
types of cancer that affect adult males worldwide [1].
Treatment options for HCC consist of surgical resection,
transcatheter arterial chemoembolization (TACE), percu-
taneous ethanol injection (PEI), radiofrequency ablation
(RFA), and radiotherapy [2–8]. A recent study showed that
low-dose radiotherapy and whole-liver irradiation were
ineffective, as they led to severe hepatic failure [9]. One
study suggested that localized high-dose radiation therapy
can improve the efficacy of radiation therapy [8], and ion
beams can provide a better dose concentration then can
photon beams [10, 11]. Indeed, ion beams are considered a
highly effective treatment for cancer due to their higher
relative biological effectiveness (RBE) [12, 13].
The response to HCC therapy can be evaluated by
measurement of changes in tumor size via a variety of
diagnostic equipment. For example, dynamic contrast-en-
hanced computed tomography (DCE-CT) and DCE-
& Masayuki Kanamoto
kanamo@u-fukui.ac.jp
1 Department of Radiology, University of Fukui Hospital, 23-3,
Shimoaizuki, Matsuoka, Eiheiji-tyo, Yoshida-gun,
Fukui 910-1193, Japan
2 Division of Health Sciences, Graduate School of Medical
Science, Kanazawa University, 5-11-80, Kodatsuno,
Kanazawa, Ishikawa 920-0942, Japan
3 Departments of Radiology, Hyogo Ion Beam Center, 1-2-1
Kouto, Shingutyo, Tatsuno, Hyogo 679-5165, Japan
4 Hyogo Ion Beam Medical Support, 1-2-1 Kouto, Shingutyo,
Tatsuno, Hyogo 679-5165, Japan
5 Japanese Red Cross Ise Hospital, 1-471-2 Funase, Ise,
Mie 516-8512, Japan
Radiol Phys Technol (2016) 9:233–239
DOI 10.1007/s12194-016-0354-5
magnetic resonance imaging (MRI) can be used for
assessment of the presence of a hypervascular tumor in the
arterial phase. However, poorly differentiated HCC shows
hypovascularity with this assessment [14]. Diffusion-
weighted imaging (DWI) is an MRI method that produces
an image based on regional differences in the random
motion of water molecules. DWI provides information
different from that of T1–weighted imaging (T1WI) and
T2–weighted imaging (T2WI). DWI can detect cellular
edema and malignant tumors due to their relative differ-
ences in cellular density. The apparent diffusion coefficient
(ADC) can be measured quantitatively in vivo based on the
diffusion of tissue. Therefore, DWI provides a greater
possibility of early assessment of the tumor when com-
pared with imaging-based analysis of tumor blood flow and
tumor conditions. Studies have described a number of
useful ADCs for the evaluation of the response to treatment
for HCC and liver metastases [15–20]. However, assess-
ment of ADC values following ion beam therapy has not
been reported previously for patients with HCC.
Our purpose in this study was to evaluate the utility of
the ADC for the assessment of the response to ion beam
therapy in patients with HCC and liver conditions.
2 Materials and Methods
2.1 Patients
Ten consecutively enrolled patients (eight men, two
women; mean age 75.0 years; age range 58–81 years) with
HCC, including 13 HCC lesions, were evaluated retro-
spectively from January 2008 to October 2012. Hepatitis B
virus infection was noted in four patients, hepatitis C virus
infection was noted in three patients, and non-alcoholic
steatohepatitis (NASH) was noted in four patients. Patient
demographic data including cause of lesion, size of tumor,
and Child-Pugh classification are given in Table 1.
This study was approved by our medical ethics board.
Informed consent was obtained from each patient at the
time of enrollment. On DWI, each tumor showed a high
signal intensity. On DCE-MRI with gadolinium ethoxy-
benzyl diethylenetriamine triamine pentaacetic acid (Gd-
EOB-DTPA) (Primovist; Bayer Schering Pharma, Berlin,
Germany), the tumor showed a low signal intensity in the
hepatobiliary phase, a high signal intensity in the arterial
phase, and a low signal intensity in the late arterial phase.
2.2 Ion beam therapy
Respiratory movement was measured by digital radiogra-
phy (DAR-3000; Shimadzu). During free breathing of the
patient, examinations were performed at 2–60 frames/s.
Movement was measured as an index of the diaphragm
during inspiration from the time the patient began to
breathe. CT treatment involved the use of multi-detector
computed tomography (MDCT; Asteion TSX-021A,
Toshiba Medical Inc.) and a breathing respiratory-gated
infrared system synchronizer (Anzai Medical Inc.). The
determination of the gross tumor volume (GTV) was per-
formed by Gd-EOB-DTPA MRI. A particle therapy plan-
ning system (XIO; CMS Japan) was also used. The clinical
target volume (CTV) and planning target volume (PTV)
were defined as follows: CTV = GTV ? 5 mm, and
PTV = CTV ? 5 mm (setup margin) ? 1 mm (internal
margin). The margin was set by inferior respiratory dis-
placement results obtained before respiratory movement.
The radiation dose was in the range of 66–76 Gy equiva-
lent (GyE) (mean dose 70 GyE) [21]. The ion beams were a
proton beam of 150 or 210 MeV and a carbon beam of
320 MeV.
2.3 MRI technique
A 1.5-T MRI system (Gyroscan Intera; Philips Medical
Systems International, Best, The Netherlands) with a sen-
sitivity encoding (SENSE) phased array coil was used, with
patients placed in the supine position. DCE-MRI and
hepatobiliary-phase images were obtained during breath
holding. For the DCE-MRI, a dose of 0.1 mL of Gd-EOB-
DTPA per kilogram of body weight was injected intra-
venously at a flow rate of 2.0 mL/s, followed by a 30-mL
saline flush administered at 2.0 mL/s. Unenhanced, double-
arterial and portal venous equilibrium, and hepatobiliary
phase images were then obtained. Images were obtained at
25, 35.5, 60, 150 s, and 20 min after injection of Gd-EOB-
DTPA. DCE-MRI and hepatobiliary phase images were
obtained with use of an enhanced T1-weighted high-reso-
lution isotropic volume examination (e-THRIVE). The
scan parameters of DCE-MRI were as follows: repetition
time (TR) 4.0 ms; echo time (TE) 1.98 ms; acquisition
time 1 phase = 10.5 s; matrix size 192 9 256; field of
view (FOV) 270 9 350 mm; number of signals averaged
(NSA) 1; flip angle 12; slice thickness 3 mm; number of
slices 70; reduction factor 1.8. The scan parameters of the
hepatobiliary phase were as follows: TR 4.1 ms; TE
2.0 ms; acquisition time 20.6 s; matrix size 240 9 400;
FOV 270 9 350 mm; NSA 1; flip angle 12; slice thick-
ness 2 mm; number of slices 100; reduction factor 1.5.
Diffusion-weighted imaging was obtained by use of
respiratory-triggered single-shot echo planar imaging
(EPI). The scan parameters were as follows: TR 1800 ms;
TE 64 ms; acquisition time 240 s; matrix size 112 9 256,
FOV 270 9 350 mm; NSA 3; flip angle 90; slice thick-
ness 5 mm; slice gap 0.5 mm; number of slices 30;
reduction factor 2.0; b value 0, 150 and 800 s/mm2.
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2.4 Image analysis and selection of regions
of interest
The ADC maps were calculated for b values of 150 and
800 s/mm2. The regions of interests (ROIs) in the ADC
maps were delineated as tumor, normal irradiated liver, and
normal non-irradiated liver. The ROI created on the trace
in the tumor included the whole tumor for all high-signal
areas on lesions referred to as DCE-MRI and a b value of
800 s/mm2 (Fig. 1). The ADC of each tumor was then
measured. The ROI of the irradiated liver was delineated at
about 50 % (35 GyE) of the prescription dose. Because the
dose distribution is steeper according to the Bragg peak,
the ROIs of the irradiated liver and of the normal liver were
set at approximately 1 cm in diameter within the right lobe
so that vessels and tumor lesions were avoided. The ROIs
created on the trace images were copied and pasted onto
the ADC map by use of the MR system. Each ADC was
measured three times. The diameter of the tumor was
measured as the largest diameter at each examination time
in DCE-MRI. The tumor reduction ratio was defined as
follows:
Fig. 1 A 60-year-old man with hepatocellular carcinoma (HCC) of
segment VII (arrows) before ion beam therapy. a T1-weighted high-
resolution isotropic volume examination (e-THRIVE) images were
acquired in the arterial phase after gadolinium ethoxybenzyl
diethylenetriamine triamine pentaacetic acid (Gd-EOB-DTPA)
administration. The region of interest (ROI) surrounding the HCC
was copied to c and d. b Hepatobiliary phase of Gd-EOB-DTPA.
c Diffusion-weighted imaging (DWI) with a b value of 800 s/mm2.
d Apparent diffusion coefficient (ADC) map with b values of 150 and
800 s/mm2. e DWI with a b value of 800 s/mm2 with dose map in
35GyE (green line). ROIs surrounding the irradiated and the normal
liver were copied to e and f. f ADC map with b values of 150 and
800 s/mm2 with dose map in 35GyE (green line). g In the arterial
phase of Gd-EOB-DTPA at the first follow-up. The ROI surrounding
the HCC was copied to h and i. h DWI with a b value of 800 s/mm2 at
the first follow-up. i ADC map with b values of 150 and 800 s/mm2 at
the first follow-up. j In the arterial phase of Gd-EOB-DTPA at the
second follow-up. The ROI surrounding the HCC was copied to k and
l. k DWI with a b value of 800 s/mm2 at the second follow-up. l ADC
map with b values of 150 and 800 s/mm2 at the second follow-up
Table 1 Patient characteristics
Patient number Size of tumor base line (mm) Size at first follow-up (mm) Size at second follow-up (mm) Segment no. Child-Pugh
class
1 18.75 10.94 6.25 S6 A
2 26.05 14.58 9.70 S4 B
3 47.54 28.70 24.3 S3 A
4 37.70 10.80 7.58 S7 A
9.17 5.47 3.40 S8
26.43 9.00 7.10 S8
5 16.00 11.10 7.00 S8 A
10.17 6.50 5.60 S7
6 22.10 20.80 9.11 S8 B
7 33.72 29.38 25.42 S6 A
8 27.36 13.71 9.20 S6 A
9 22.36 18.33 14.43 S6 A
10 21.87 13.26 10.98 S8 A
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Reduction ratio ¼ 100 DpreDpost
 
=Dpre;
where Dpre is a multiplicative of the largest diameter of the
tumor before ion therapy, and Dpost is a multiplicative of
the largest diameter of the tumor after ion therapy.
2.5 Follow-up
Patients were examined by Gd-EOB-DTPA MRI at
3 months (first follow-up) and 6 months (second follow-
up) after ion beam therapy. The same MRI machine was
used before and after the therapy.
2.6 Statistical Analysis
All statistical analyses were performed by use of GraphPad
software (Prism version 5.02, San Diego, CA, USA). Two-
sided tests were used, and P\ 0.05 was considered to
indicate statistical significance. The ADC values, as well as
the maximum tumor sizes, before and after ion beam
therapy were compared by use of the Friedman test. The
tumor reduction ratios before and after ion beam therapy
were compared by use of the Wilcoxon t test.
The relationship among ADC values of the tumor,
irradiated liver, normal liver, and each time point was
compared by Kruskal–Wallis test. The relationship
between the tumor reduction ratio at each follow-up and
the ADC of the tumor values was assessed by linear
regression analysis.
3 Results
The differences in ADC values among the various liver
tissues are shown in Table 2. The ADC of the tumors was
significantly higher after therapy than before therapy
(P\ 0.001). The ADC of the irradiated liver was also
significantly higher after therapy than before therapy
(P = 0.007). However, the ADC of the normal liver did
not change in response to therapy (P[ 0.05). The ADC of
the tumor tended to be higher after therapy than before
therapy. Moreover, the maximum tumor size tended to
Table 2 ADC values,
maximum tumor size, and
tumor reduction ratio before and
after ion beam therapy
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decrease after therapy when compared with the size before
therapy (P\ 0.001). The relationship between the tumor
reduction ratio and the imaging time point is shown in
Table 2. A strong correlation was found between the tumor
reduction ratio and the imaging time point (R = 0.73,
P = 0.006).
The relationship between the ADC values of each organ
and any time point is shown in Fig. 2. The differences in
ADC among the baseline groups were not statistically
significant (P[ 0.05), whereas those among the first fol-
low-up groups were statistically significant (P\ 0.01).
There was a significant difference between the ADC of the
tumor and the ADC of the normal liver at the first follow-
up time point (P\ 0.01). Further, there was a significant
difference between the ADC of the normal liver and the
ADC of the irradiated liver (P\ 0.05). In addition, there
was a significant difference between the ADC of the tumor
and the ADC of the irradiated liver (P\ 0.05).
The differences in ADC among the second follow-up
groups were statistically significant (P[ 0.001). There was
a significant difference between the ADC of the tumor and
that of the normal liver at the second follow-up
(P\ 0.001). Further, there was also a significant difference
between the ADC of the normal liver and that of the irra-
diated liver (P\ 0.01), and there was a significant differ-
ence between the ADC of the tumor and that of the
irradiated liver (P\ 0.05).
In addition, there was no correlation between the tumor
reduction ratio and the ADC of the tumor (P[ 0.05), as
shown in Fig. 3a, b. In all patients, the DCE-MRI after ion
beam therapy showed tumor necrosis. The finding in a
60-year-old man with HCC of segment VII is illustrated in
Fig. 4.
4 Discussion
In the present study, we evaluated the state of HCC after
ion beam therapy by analyzing the ADC. Chen et al.
measured the ADC value in HCC before and after TACE as
a way of monitoring the response to treatment. They
reported a significant increase in ADC values in HCC in
response to TACE [15]. However, the ADC values were
measured only for a short period of a few days after TACE.
By contrast, in the present study we examined the ADC at
longer time points after treatment.
In this study, the tumor ADC value increased signifi-
cantly in response to treatment (Table 2). Malignant
tumors have a high cell density. After treatment, tumor
necrosis causes destruction of the cell membrane, and there
is a resulting increase in water diffusion to the extracellular
space. A decrease in the ADC value corresponds to a
decrease in local diffusion, and an increase in the ADC
value results in relaxation of limited diffusion, as observed
in tumor cell death [22]. This result indicates that ion beam
therapy results in necrosis and an increase in ADC values.
The ADC value of the irradiated liver had increased
significantly by the time of the second follow-up (Table 2).
In photon therapy, the liver threshold of photon exposure is
defined as 30–35 Gy. However, even when the liver was
irradiated with less than 35 Gy, the ADC values were
reported to have increased significantly [16]. On the other
hand, the ADC values at the time of the first follow-up were
Fig. 3 Relationship between
tumor size reduction and ADC
value at various time points.
a First follow-up, and b second
follow-up
Fig. 2 Relationship between apparent diffusion coefficient (ADC)
values and various time points of liver after ion beam therapy. ns not
significant
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significantly different when we compared the irradiated liver
and the normal liver, suggesting that the increases in ADC
values were not necessarily consistent with the prescription
dose for compared photon and ion beam. This fact suggests
that the ADC values are different due to differences in the
irradiation dose to the liver (Fig. 2).
Post-treatment DCE-MRI showed necrosis in all tumors.
In highly vascular tissues, such as those in the liver, perfusion
or blood flow cause significant signal decay when a low
b value is used [23]. By contrast, a high b value almost
completely excludes the effects of in vivo perfusion. Several
previous studies utilized 0 and another b value, which makes
it difficult to analyze the different components of ADC in
detail [15, 16, 18–20, 22]. To avoid the effect of perfusion,
we used b values of 150 and 800 in this study. TheADC in the
irradiated liver is related to inflammation of the liver rather
than to local elevation of blood flow to the liver. Moreover,
the ADC values of the tumor and irradiated liver were
increased at the time of the second follow-up. The tumor
reduction ratio had increased significantly by the time of the
second follow-up (Fig. 2), which is consistent with the cur-
rent understanding that tumors decrease at a rapid pace until
6 months after ion beam therapy.
Generally, radiotherapy makes tumor necrosis or
increase in extracellular space water diffusion, and increase
in ADC value of the tumor [24]. We had speculated that the
rate of tumor necrosis was related to the increased ADC
values, but there was no correlation between the tumor
reduction ratio and ADC values in our study (Fig. 3a, b).
On the other hand, Koh et al. reported that there was a
linear inverse correlation between the tumor reduction ratio
and the ADC, and that the ADC increased significantly in
the group of patients that responded to therapy [17].
However, Cui et al. reported that there was a weaker
correlation between the tumor reduction ratio and the
pretreatment ADC [20]. These observations suggest that
the ADC of the tumor differs depending on treatment.
Moreover, tumor histology and efficacy of therapy may be
useful in predicting the response to therapy.
The risk of inducing hepatic dysfunction should be
considered when any therapy for HCC is utilized, espe-
cially in patients with chronic liver disease, such as cir-
rhosis or chronic hepatitis. Even when treatment is
considered to have been successful, one must consider that
HCC and intrahepatic metastasis are associated with the
occurrence of chronic liver disease. Therefore, HCC
treatments that are relatively noninvasive and that provide
high local control are particularly beneficial. Although ion
beam therapy appears to fulfill these criteria, it is often not
a feasible option because most institutions currently do not
have the facilities for this treatment modality.
Moreover, locally irradiated liver tissues have a dimin-
ished uptake of the Gd-EOB-DTPA in the liver par-
enchyma [25]. Although it is difficult to analyze the
irradiated liver after the therapy, it can be evaluated in a
non-invasive manner in tumors and in the liver by analysis
of the ADC value.
This study has several limitations. First, the patient
population was relatively small. Second, no pathologic
evaluation was performed. Third, the ADC values were
calculated by monoexponential analysis of the signal in this
study, whereas bi-exponential analysis may have provided
more detailed information regarding focal tissue non-in-
vasively [26]. Fourth, recent studies have compared pre-
treatment of the ADC of the tumor with the tumor
reduction ratio. It was discussed whether it was a predictive
response to therapy or not. However, we compared the
tumor reduction ratio to the after therapy of ADC of tumor
Fig. 4 A 60-year-old man with hepatocellular carcinoma (HCC) of
segment VII (arrows). a Ion beam therapy planning. b Diffusion-
weighted imaging (DWI) with a b value of 800 s/mm2 before ion
beam therapy, c after ion beam therapy at the time of the first follow-
up, and d after ion beam therapy at the time of the second follow-up.
e ADC map with b values of 150 and 800 s/mm2 before ion beam
therapy. ADC value of tumor = 0.88 (9 10-3 mm2/s), irradiated
liver = 0.92 (9 10-3 mm2/s), normal liver = 0.89 (9 10-3 mm2/s).
f After ion beam therapy at the time of the first follow-up, ADC value
of tumor = 1.26 (9 10-3 mm2/s), irradiated liver = 1.15 (9 10-3
mm2/s), normal liver = 0.89 (9 10-3 mm2/s). g After ion beam
therapy at the time of the second follow-up, ADC value of
tumor = 1.68 (9 10-3 mm2/s), irradiated liver = 1.28 (9 10-3
mm2/s), normal liver = 0.85 (9 10-3 mm2/s)
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at each follow-up. In this study, all tumors showed a
reduction in size after therapy, and the ADC of the tumor
was significantly higher before than after therapy.
5 Conclusion
Inflammation of the liver occurs after treatment as a result
of radiation doses from an ion beam, and the tumor reaches
a state of necrosis. ADC value analysis provides a non-
invasive assessment and yields focal information regarding
the tumor and liver before and after ion beam therapy.
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